AstraZeneca PLC ADR closed 22.59% below its 52-week high of $87.68, which the company achieved on August 30th.

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a new study.

Two years ago, the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group faced a mini-exodus as several ...

AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and ...

CompanyOverview|NASDAQ:CLLS] Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

The investment will create more than 12,000 jobs, Roche said — 1,000 with the company, and the remainder to support new U.S.

AstraZeneca PLC ADR closed 23.70% below its 52-week high of $87.68, which the company reached on August 30th.

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...

Interim results from a Phase III trial showed the combo benefited HER2-positive metastatic breast cancer patients in the first-line setting.